A phase I, prospective, mono-center, double-blinded, randomized, controlled study to assess the safety and tolerability of intraarticular injection of PLX-PAD cells for the treatment of mild to moderate knee osteoarthritis – PROTO–I

2024-517421-12-00 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 7 Jan 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 18
Countries 1
Sites 1

Osteoarthritis

Key facts

Sponsor
Charite Universitaetsmedizin Berlin KöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
7 Jan 2026 → ongoing
Decision date (initial)
2025-05-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517421-12-00
WHO UTN
U1111-1317-3338

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Osteoarthritis

VersionLevelCodeTermSystem organ class
21.1 LLT 10023476 Knee osteoarthritis 10028395

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Charite Universitaetsmedizin Berlin KöR

Sponsor organisation
Charite Universitaetsmedizin Berlin KöR
Address
Chariteplatz 1, Mitte Mitte
City
Berlin
Postcode
10117
Country
Germany

Scientific contact point

Organisation
Charite Universitaetsmedizin Berlin KöR
Contact name
Trial centre

Public contact point

Organisation
Charite Universitaetsmedizin Berlin KöR
Contact name
Trial centre

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 18 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Charite Universitaetsmedizin Berlin KöR
Centrum für Muskuloskeletale Chirurgie, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-01-07 2026-01-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-05 Germany Acceptable
2025-05-30
2025-05-30
2 SUBSTANTIAL MODIFICATION SM-1 2026-04-14 Germany Acceptable
2026-05-07
2026-05-08